Novel gene therapy approach for nasopharyngeal carcinoma (Q35008899)

5 August 2017

1 reference

title

Novel gene therapy approach for nasopharyngeal carcinoma (English)

1 reference

5 August 2017

0 references

Fei-Fei Liu

1

0 references

publication date

1 December 2002

1 reference

Seminars in Cancer Biology

5 August 2017

published in

1 reference

5 August 2017

volume

12

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

505-515

1 reference

Retrospective analysis on treating nasopharyngeal carcinoma with accelerated fractionation (6 fractions per week) in comparison with conventional fractionation (5 fractions per week): report on 3-year tumor control and normal tissue toxicity

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience.

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Cancer gene therapy: scientific basis.

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Gene therapy of human disease

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Gene therapy. Viral vectors still pack surprises

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Gene therapy -- promises, problems and prospects

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors.

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Development of optimized vectors for gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Cationic liposome-mediated intravenous gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Gene therapy. Safer and virus-free?

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Myocardial gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Genetic targeting of adenoviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Conditional gene targeting for cancer gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Molecular targeting of gene therapy and radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Heat-directed gene targeting of adenoviral vectors to tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Molecular approaches to chemo-radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Development of synthetic promoters for radiation-mediated gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and -negative nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Reovirus therapy of tumors with activated Ras pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Molecular pathology parameters in human nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Assessment of p53 expression in nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Expression of bcl-2-, p53, and Ki-67 and outcome of patients with primary nasopharyngeal carcinomas following DNA-damaging treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

P53 gene replacement for cancer--interactions with DNA damaging agents

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Adenovirus-p53 gene therapy in human nasopharyngeal carcinoma xenografts.

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Suppression of human nasopharyngeal carcinoma cell growth in nude mice by the wild-type p53 gene

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Absence of nuclear p16 from Epstein-Barr virus-associated undifferentiated nasopharyngeal carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Epstein-Barr virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Morphological transformation of human keratinocytes expressing the LMP gene of Epstein Barr virus

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Regulation of cell growth and death by Epstein-Barr virus

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Transcriptional activation of NF-kappa B activity by Epstein-Barr virus (EBV) LMP1 as a selective therapeutic strategy for EBV-associated diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma.

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

EBP2, a human protein that interacts with sequences of the Epstein-Barr virus nuclear antigen 1 important for plasmid maintenance.

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Identification of EBNA1 amino acid sequences required for the interaction of the functional elements of the Epstein-Barr virus latent origin of DNA replication

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Use of EBV-based Vector/HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

A strategy for specific targeting of therapeutic agents to tumour cells of virus-associated cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: comparison of two different Epstein-Barr virus-based vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Proliferation, cell cycle and apoptosis in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

A matter of life and cell death

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Suppression of apoptosis: role in cell growth and neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Dissecting the pathways to death

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

The kiss of death: promises and failures of death receptors and ligands in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Death receptors: signaling and modulation

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Radiation-induced expression of functional Fas ligand in EBV-positive human nasopharyngeal carcinoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Downregulation of Fas ligand by shedding

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Apoptosis by death factor

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Analysis of the expression of Fas-L in nasopharyngeal carcinoma tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt.

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Bcl-2 and LMP1 expression in nasopharyngeal carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

Life-or-death decisions by the Bcl-2 protein family.

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

EBV persistence in memory B cells in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1044579X02000937

7 January 2021

10.1016/S1044579X02000937

Identifiers

DOI

1 reference

5 August 2017

1 reference